
AtaiBeckley Inc
ATAIHealthcare|Biotechnology|USA
$5.17
-0.16 (-3.00%)
Tangible Book
$0.54
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
1.16,
0.37,
1.36,
24.8,
190.38
],
"ebit_estimate": [
-150.94,
-167.48,
-174.85,
-131.88,
-25.13
],
"ebitda_estimate": [
-139.93,
-156.67,
-169.87,
-197.63,
-138.93
],
"net_income_estimate": [
-142.15,
-166.63,
-171.86,
-162.26,
-77.14
],
"per_share_eps_estimate": [
-0.42,
-0.43,
-0.41,
-0.29,
-0.09
],
"eps_nri_estimate": [
-0.38,
-0.41,
-0.41,
-0.4,
-0.19
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
0.45,
0.48,
0.35,
0.56,
0.21
],
"pretax_income_estimate": [
-143.26,
-162.29,
-171.86,
-120.45,
1.15
],
"operating_cash_flow_per_share_estimate": [
-0.28,
-0.31,
-0.26,
-0.37,
-0.33
],
"roa_estimate": [
-65.2,
-68.2,
-71.6,
-87.7,
-75.1
],
"roe_estimate": [
-73.45,
-88.05,
-108.85,
-102.75,
-117.95
],
"gross_margin_estimate": [
60,
60,
78,
73.2,
85.43
],
"operating_cash_flow_estimate": [
-100.08,
-110.8,
-91.14,
-132.25,
-116.16
],
"pettm_estimate": [
0,
0,
0,
0,
0
],
"long_term_growth_rate_mean": 8.77,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 44.55,
"future_eps_nri_estimate_growth": 8.77,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": -14.86,
"future_ebitda_estimate_growth": 32.62,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -10.47,
"future_pretax_income_estimate_growth": 32.37,
"future_book_value_per_share_estimate_growth": -14.93,
"future_roa_estimate_growth": 34.11,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 14.8
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
0.01,
0.01,
0.2,
null,
null,
null,
0.23
],
"ebit_estimate": [
-36.93,
-40.14,
-42.97,
-41.29,
-42.35,
-43.77,
-44.33
],
"ebitda_estimate": [
-34.2,
-36.47,
-38.47,
null,
null,
null,
null
],
"net_income_estimate": [
-34.23,
-37.37,
-39.74,
-41.86,
-42.93,
-44.3,
-44.57
],
"per_share_eps_estimate": [
-0.11,
-0.11,
-0.12,
-0.1,
-0.11,
-0.11,
-0.11
],
"eps_nri_estimate": [
-0.1,
-0.1,
-0.11,
-0.09,
-0.1,
-0.1,
-0.1
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
0.48,
0.42,
0.61,
0.55,
0.48,
0.4,
0.32
],
"pretax_income_estimate": [
-34.71,
-37.64,
-40.84,
-41.86,
-42.93,
-44.33,
-44.57
],
"operating_cash_flow_per_share_estimate": [
-0.06,
-0.06,
-0.06,
-0.06,
-0.07,
-0.07,
-0.08
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
50,
50,
50,
70,
70,
70,
70
],
"operating_cash_flow_estimate": [
-21.45,
-21.45,
-21.45,
-21.45,
-25.02,
-25.02,
-28.59
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 8.77,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 44.55,
"future_eps_nri_estimate_growth": 8.77,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": -14.86,
"future_ebitda_estimate_growth": 32.62,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -10.47,
"future_pretax_income_estimate_growth": 32.37,
"future_book_value_per_share_estimate_growth": -14.93,
"future_roa_estimate_growth": 34.11,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 14.8
}